329 related articles for article (PubMed ID: 32946647)
1. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals.
Shiha G; Waked I; Soliman R; Elbasiony M; Gomaa A; Mikhail NNH; Eslam M
Liver Int; 2020 Nov; 40(11):2828-2833. PubMed ID: 32946647
[TBL] [Abstract][Full Text] [Related]
2. Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk-based surveillance using pre- and post-treatment general evaluation score.
Shiha G; Soliman R; Mikhail N; Hassan A; Eslam M
Liver Int; 2021 Nov; 41(11):2768-2776. PubMed ID: 34174150
[TBL] [Abstract][Full Text] [Related]
3. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
Azzi J; Dorival C; Cagnot C; Fontaine H; Lusivika-Nzinga C; Leroy V; De Ledinghen V; Tran A; Zoulim F; Alric L; Gournay J; Bronowicki JP; Decaens T; Riachi G; Mikhail N; Soliman R; Shiha G; Pol S; Carrat F; Ganne-Carrié N;
Clin Res Hepatol Gastroenterol; 2022; 46(6):101923. PubMed ID: 35405354
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
5. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
[TBL] [Abstract][Full Text] [Related]
6. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
7. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
8. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G; Pla A; Granel N; Bartres C; Llarch N; Vilana R; Nuñez I; Darnell A; Belmonte E; García-Criado A; Díaz A; Muñoz-Martinez S; Ayuso C; Bianchi L; Fuster-Anglada C; Rimola J; Forner A; Torres F; Bruix J; Forns X; Reig M
J Hepatol; 2022 Apr; 76(4):874-882. PubMed ID: 34856322
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
12. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M
J Hepatol; 2022 Apr; 76(4):812-821. PubMed ID: 34871626
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
Ahumada A; Rayón L; Usón C; Bañares R; Alonso Lopez S
World J Gastroenterol; 2021 Oct; 27(40):6737-6749. PubMed ID: 34790004
[TBL] [Abstract][Full Text] [Related]
14. Shear-wave elastography to predict hepatocellular carcinoma after hepatitis C virus eradication: A systematic review and meta-analysis.
Esposto G; Santini P; Galasso L; Mignini I; Ainora ME; Gasbarrini A; Zocco MA
World J Gastroenterol; 2024 Mar; 30(10):1450-1460. PubMed ID: 38596502
[TBL] [Abstract][Full Text] [Related]
15. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
16. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
18. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
19. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
Chun HS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee CH; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Lee JH; Kim SU
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):378-385. PubMed ID: 32011388
[TBL] [Abstract][Full Text] [Related]
20. International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients.
Shiha G; Soliman R; Mikhail NNH; Carrat F; Azzi J; Nathalie GC; Toyoda H; Uojima H; Nozaki A; Takaguchi K; Hiraoka A; Atsukawa M; Abe H; Matsuura K; Mikami S; Watanabe T; Tsuji K; Ishikawa T; Suri V; Osinusi A; Ni L; Zou J; Sarin SK; Kumar M; Jalal PK; Hashim MA; Hassan M; Lopez SA; Bañares R; Ahumada AM; Mousa NH; Eslam M; Waked I
J Viral Hepat; 2022 Sep; 29(9):807-816. PubMed ID: 35657138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
